Search Results - application+%3e+vaccines

212 Results Sort By:
A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics
BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome...
Published: 12/10/2024   |   Inventor(s): Ursula Buchholz
Keywords(s):  
Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
A Key Advancement for Human Norovirus Research and Reverse Genetics
The HEK293T/T7 cell line is a novel development in virology research, particularly for studying human noroviruses. This cell line expresses the T7 RNA polymerase, a key enzyme used in reverse genetics systems. Unlike existing technologies, the HEK293T/T7 cell line offers the unique advantage of being able to produce functional T7 RNA polymerase, which...
Published: 12/10/2024   |   Inventor(s): Carlos Sandoval-Jaime, Stanislav Sosnovtsev
Keywords(s):  
Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases
Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense
The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent...
Published: 12/10/2024   |   Inventor(s): Zhao Chun Chen, Robert Purcell, Mahtab Moayeri, Stephen Leppla
Keywords(s):  
Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies
This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram,...
Published: 12/10/2024   |   Inventor(s): Zhaochun Chen, Robert Purcell, Joseph Blaney
Keywords(s):  
Category(s): Application > Diagnostics, Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Antibodies, ResearchProducts > Research Equipment, TherapeuticArea > Infectious Disease
Replicative-Defective Mutant Human Cytomegalovirus: Potential Applications in Vaccinology and Cancer Immunotherapy
The potential applications of a replicative-defective mutant form of human cytomegalovirus (HCMV) are significant in the fields of vaccinology and cancer immunotherapy. This innovative approach involves engineering a mutant HCMV that can selectively target specific cells. Firstly, it holds promise as a vaccine candidate for protecting against HCMV infection,...
Published: 12/10/2024   |   Inventor(s): Jeffrey Cohen, John Bowman
Keywords(s):  
Category(s): Application > Diagnostics, Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, ResearchProducts > Computational models/software
Monoclonal Antibodies That Bind to the Underside of Influenza Viral Neuraminidase
Current influenza vaccines mainly induce antibodies against the surface glycoprotein hemagglutinin (HA) that block viral attachment to its host receptors and viral membrane fusion to the host cell. The immunodominant head region of HA undergoes antigenic drift and antibodies directed to the head confer little cross-protections between strains or subtypes. ...
Published: 10/31/2024   |   Inventor(s): Masaru Kanekiyo, Sarah Andrews, Julia Lederhofer, Yaroslav Tsybovsky
Keywords(s):  
Category(s): Application > Consumer Products, Application > Research Materials, Application > Therapeutics, Application > Vaccines, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Immunogens, Compositions, and Methods for the Treatment of Dyslipidemia
This technology includes a novel vaccine for forming autoantibodies against apoC-III, a plasma enzyme that inhibits lipolysis. The vaccine can possibly be used to treat patients with high triglycerides and are at risk for pancreatitis and cardiovascular disease. This disclosure describes an ApoC3 immunogen that includes an antigenicApoC3 peptide linked...
Published: 8/12/2024   |   Inventor(s): Alan Remaley
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Metabolic Disease
Compositions and Methods for Reducing Serum Triglycerides
This technology includes a vaccine for lowering plasma triglycerides by inducing the formation of autoantibodies against either ANGPTL3 or ANGPTL4, which are inhibitors of Lipoprotein Lipase. This was done by conjugating synthetic peptides based on ANGPTL3 or ANGPTL4 to virus- like particles (VLPS). Injection of the vaccine in animal models was shown...
Published: 9/11/2024   |   Inventor(s): Alexandra Fowler, Alan Remaley, Marcelo Amar, Bryce Chackerian
Keywords(s):  
Category(s): Application > Therapeutics, Application > Research Materials, Application > Vaccines, Collaboration Sought > Licensing, TherapeuticArea > Cardiology
Alpha-galactosidase-A Knockout Mouse Model for Studying Fabry Disease
This technology includes an alpha-galactosidase-A knockout mouse model that can be used to study Fabry disease, an X-linked lysosomal storage disorder. Alpha-galactosidase-A is a crucial enzyme responsible for the breakdown of glycolipids, particularly globotriaosylceramide (Gb3), within lysosomes. In Fabry disease, a rare and inherited lysosomal storage...
Published: 4/8/2024   |   Inventor(s): Toshio Ohshima, Ashok Kulkarni, Roscoe Brady, Gary Murray
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Application > Vaccines, Collaboration Sought > Materials Available, ResearchProducts > Animal Models, TherapeuticArea > Rare / Neglected Diseases, TherapeuticArea > Metabolic Disease
High Efficacy Vaccine and Microbicide Combination For Use Against HIV
Abstract: Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant...
Published: 8/5/2024   |   Inventor(s): Genoveffa Franchini, Marjorie Robert-Guroff, Daniel Appella, Sabrina Helmold Hait, Mohammed Rahman, Massimiliano Bissa, Ettore Appella, Lisa Marie Jenkins, Isabela Silva De Castro
Keywords(s): Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Vaccines
1 2 3 4 5 6 7 8 9 10 ...